Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 14, 2003. The report serves as a notification of changes in director interests regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within an employee retirement plan.
Material Changes
The primary material change reported is a decrease in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: April 10, 2003
- Previous Holdings: 18,586,757 ADRs
- New Holdings: 18,523,131 ADRs
- Average Price: $38.32
Management Commentary and Risks
The filing clarifies that the Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, Director Dr. J P Garnier is potentially interested in the shares held in the fund in the same manner as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of the reporting date.
- Confirm the specific impact of the fund movement on Director Dr. J P Garnier's reported interests.
- Note that this filing does not contain operational or financial performance data for the quarter.